Feedback
Settings

Settings

Goto Application

2,402 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12P AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 241
1.WO/2023/118424ALPHA-1 ANTITRYPSIN PRODUCED FROM YEAST FOR USE IN THE TREATMENT OF VIRAL INFECTIONS
WO - 29.06.2023
Int.Class C12P 21/02
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21Preparation of peptides or proteins
02having a known sequence of two or more amino acids, e.g. glutathione
 Appl.No PCT/EP2022/087461 Applicant AATEC MEDICAL GMBH Inventor STANGL, Manfred
The invention relates to a recombinant human alpha 1-antitrypsin (AAT) protein or a fragment thereof expressed in a genetically modified yeast for use in the treatment of a viral infection and/or lung inflammation. In one embodiment, the viral infection is a viral respiratory infection, preferably a coronavirus infection, such as a SARS CoV infection, more preferably SARS-CoV-2. The invention further relates to a method of producing recombinant AAT protein or fragment(s) thereof from genetically modified yeast. In embodiments, the method comprises the steps of culturing a genetically modified yeast comprising an exogenous nucleic acid molecule with an AAT-encoding region operably linked to a promoter or promoter/enhancer combination, expressing recombinant AAT in the cultured yeast, and isolating recombinant AAT from the culture. In embodiments, the recombinant AAT produced from yeast is prepared in a pharmaceutical composition, such as a solution, preferably suitable for nebulization and subsequent inhalation by a subject.
2.WO/2024/261142A RECOMBINANT HUMAN ALPHA-1 ANTITRYPSIN GLYCOPROTEIN
WO - 26.12.2024
Int.Class A61K 38/55
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
55Protease inhibitors
 Appl.No PCT/EP2024/067275 Applicant AATEC MEDICAL GMBH Inventor JANKOWSKY, Rüdiger
The invention relates to a recombinant human alpha1-antitrysin (rhAAT) glycoprotein or fragment thereof. In embodiments, the rhAAT or fragment has one or more N-linked glycosylations, comprising at least one HexNAc1 glycosylation. In other embodiments, the rhAAT glycoprotein or fragment thereof comprises at least one Hex9HexNAc2, Hex10HexNAc2, Hex11HexNAc2, Hex12HexNAc2, Hex13HexNAc2, Hex14HexNAc2, Hex15HexNAc2 and/or Hex16HexNAc2 glycosylation. The invention further relates to a protein preparation comprising recombinant human alpha1-antitrysin (rhAAT) glycoproteins or fragments thereof with heterologous N-linked glycosylations. In embodiments, the rhAAT protein or fragment thereof is expressed in Pichia pastoris. The invention further relates to methods for producing the rhAAT of the invention. The invention further relates to a pharmaceutical composition comprising the rhAAT glycoprotein or fragment thereof or protein preparation. The invention also relates to the rhAAT glycoprotein or fragment thereof, protein preparation or pharmaceutical composition for use in the treatment of various medical conditions, for example for the treatment of viral infections, viral respiratory infections, bacterial infections and/or bacterial respiratory infections, other respiratory or vascular diseases, and/or for the treatment of inflammatory lung disease.
3.4480960A RECOMBINANT HUMAN ALPHA-1 ANTITRYPSIN GLYCOPROTEIN
EP - 25.12.2024
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
 Appl.No 23181083 Applicant AATEC MEDICAL GMBH Inventor JANKOWSKY RÜDIGER
The invention relates to a recombinant human alphal -antitrysin (rhAAT) glycoprotein or fragment thereof. In embodiments, the rhAAT or fragment has one or more N-linked glycosylations, comprising at least one HexNAc1 glycosylation. In other embodiments, the rhAAT glycoprotein or fragment thereof comprises at least one Hex9HexNAc2, Hex10HexNAc2, Hex11 HexNAc2, Hex12HexNAc2, Hex13HexNAc2, Hex14HexNAc2, Hex15HexNAc2 and/or Hex16HexNAc2 glycosylation. The invention further relates to a protein preparation comprising recombinant human alpha1-antitrysin (rhAAT) glycoproteins or fragments thereof with heterologous N-linked glycosylations. In embodiments, the rhAAT protein or fragment thereof is expressed in Pichia pastoris. The invention further relates to a pharmaceutical composition comprising the rhAAT glycoprotein or fragment thereof or protein preparation. The invention also relates to the rhAAT glycoprotein or fragment thereof, protein preparation or pharmaceutical composition for use in the treatment of a viral respiratory infection.
4.20230073461CORONAVIRUS VACCINE
US - 09.03.2023
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No 17699035 Applicant BioNTech SE Inventor Ugur Sahin

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

5.WO/2022/060900SHARK-DERIVED BINDING MOLECULES FOR SARS-COV-2 CORONAVIRUS AND USES THEREOF
WO - 24.03.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
 Appl.No PCT/US2021/050545 Applicant THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. Inventor JOYCE, Michael Gordon
Disclosed herein are shark-derived antibodies and binding molecules with high binding affinity for SARS-CoV-2 coronavirus and the use thereof. Some of the shark-derived antibodies and binding molecules also demonstrate cross-reactivity with and neutralization of other related sarbecoviruses. The complementarity determining region (CDR) sequences and binding characteristics for these antibodies and binding molecules are provided. Also disclosed are the use of these antibodies and binding molecules to detect SARS-CoV-2 coronavirus or other related sarbecoviruses or to prevent or treat SARS-CoV-2 coronavirus or other related sarbecovirus infections.
6.20230313121MODIFIED FILAMENTOUS FUNGI FOR PRODUCTION OF EXOGENOUS PROTEINS
US - 05.10.2023
Int.Class C12N 1/14
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
14Fungi ; Culture media therefor
 Appl.No 17924927 Applicant DYADIC INTERNATIONAL (USA), INC. Inventor Marika Vitikainen

The present invention relates to genetically modified ascomycetous filamentous fungi, particularly of the species Thermothelomyces heterothallica, having reduced activity or expression of KEX2 and/or ALP7, said filamentous fungi is capable of producing elevated amounts and stability of an exogenous protein.

7.3179763COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF
CA - 14.10.2021
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
 Appl.No 3179763 Applicant ADAGIO THERAPEUTICS, INC. Inventor BELK, JONATHAN
The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S. Further disclosed are conjugates of anti-CoV-S antibodies, and binding fragments thereof, conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the disclosure include the use of anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses, or the S protein thereof, and conditions where neutralization or inhibition of coronaviruses, or the S protein thereof, would be therapeutically and/or prophylactically beneficial.
8.WO/2024/026556MODIFIED CORONAVIRUS S PROTEIN
WO - 08.02.2024
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No PCT/CA2023/050590 Applicant ARAMIS BIOTECHNOLOGIES INC. Inventor D'AOUST, Marc-andré
The present disclosure relates to modified coronavirus S protein and virus-like particles (VLPs) comprising modified coronavirus S protein. The present invention also relates to methods of increasing the purity, and/or stability of coronavirus S protein or VLPs comprising modified coronavirus S protein in a host or host cell.
9.20240252622Nucleic acid vaccine against the SARS-CoV-2 coronavirus
US - 01.08.2024
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No 18615472 Applicant INSTITUT PASTEUR Inventor Etienne Simon-Loriere

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-COV-2), comprising a nucleic acid construct encoding a SARS-COV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.

10.WO/2022/047575MODIFIED CORONAVIRUS STRUCTURAL PROTEIN
WO - 10.03.2022
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
 Appl.No PCT/CA2021/051201 Applicant MEDICAGO INC. Inventor LAVOIE, Pierre-Olivier
Modified coronaviras spike (S)-protein, virus-like particle (VLPs) comprising the modified S protein and nucleic acids encoding modified S protein are provided. Methods for modified S-protein and VLP production in a host or host cell are also described. The modified S-protein may comprise a transmembrane domain (TM) or portion of a TM, and a cytosolic tail (CT) or of a CT, wherein the CT or portion of the CT is derived from an influenza hemagglutinin (HA) protein and wherein the TM or portion of the TM is heterologous to the CT or portion of the CT. In addition a method for inducing immunity to a coronaviras infection in a subject, comprising administering a composition comprising the modified coronaviras (S)-protein or VLP to the subject is described.
# -